Quality of life measures in systemic lupus erythematosus: a systematic review
Accepted: 12 January 2022
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
In this study we systematically investigated the health-related quality of life (HRQoL) tools, which have been most often used over the last five years to evaluate the QoL in patients with systemic lupus erythematosus (SLE), focusing on their items and applications. A detailed literature search was conducted: the inclusion criteria were as follows: 1) studies including at least 50 patients; 2) studies including at least 25 patients with SLE; 3) quality of life testing with validated measures. The systematic review was based on 119 studies for a total of 32,449 SLE patients and 3092 controls. A total of 35 different patients-reported quality of life measures, applied in cohorts of patients with SLE, were retrieved with the 36-item Medical Outcome Short Form (SF-36) (63 studies of 119 =52.95%), Lupus Quality of Life (LupusQoL) (17 studies =14.3%) and Lupus Patient-Reported Outcome (LupusPRO) (12 studies =10%) being the most commonly used tools. Overall, this systematic review of the literature indicated that quality of life in patients with SLE appears to be poor and generally lower compared to both the general population and patients with other chronic conditions, as was shown by a few studies that used SF-36 and LupusPRO. The use of HRQoL scoring in SLE is gaining increasing interest and is used both in randomized controlled trials and in real-life. Future efforts are needed to improve the understanding of the impact of the disease burden on quality of life from the patient’s perspective.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- L. Punzi, R. Ramonda, Psoriatic arthritis. When the heterogeneity requires normality , Reumatismo: Vol. 64 No. 2 (2012)
- M. S. Dag, I. H. Turkbeyler, Z. A. Ozturk, B. Kısacık, E. Tutar, A. Kadayıfçı, Cytomegalovirus ileocolitis in a rheumatoid arthritis patient: case report and literature review , Reumatismo: Vol. 67 No. 1 (2015)
- G. Ciancio, A. Bortoluzzi, M. Govoni, Epidemiology of gout and chondrocalcinosis , Reumatismo: Vol. 63 No. 4 (2011): Special issue • Microcrystalline Arthritis
- M. Mazzantini, O. Di Munno, Glucocorticoid-induced osteoporosis: 2013 update , Reumatismo: Vol. 66 No. 2 (2014)
- F. Salaffi, A. Stancati, M. Carotti, R. Lorenzetti, W. Grassi, The impact of vertebral fractures on quality of life in postmenopausal women with osteoporosis. Validity of the Italian version of mini-Osteoporosis Quality of Life Questionnaire , Reumatismo: Vol. 57 No. 2 (2005)
- R.C. Ansell, T. Shuto, N. Busquets-Perez, E.M.A. Hensor, H. Marzo-Ortega, D. McGonagle, The role of biomechanical factors in ankylosing spondylitis: the patient’s perspective , Reumatismo: Vol. 67 No. 3 (2015)
- S. Parisi, M. Bruzzone, C. Centanaro Di Vittorio, A. Laganà, C.L. Peroni, E. Fusaro, Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids , Reumatismo: Vol. 65 No. 6 (2013)
- C. Bruni, S. Bellando-Randone, L. Gargani, E. Picano, A. Pingitore, M. Matucci-Cerinic, S. Guiducci, Critical finger ischemia and myocardial fibrosis development after sudden interruption of sildenafil treatment in a systemic sclerosis patient , Reumatismo: Vol. 68 No. 2 (2016)
- B.K. Singh, S. Singh, Systemic lupus erythematosus and infections , Reumatismo: Vol. 72 No. 3 (2020)
- S. Scriffignano, F.M. Perrotta, M. Ricci, B. Carabellese, E. Lubrano , Visceral muscle dysmotility syndrome in systemic lupus erythematosus: which is the role of 18 fluorodeoxyglucose-positron emission tomography-computed tomography? A clinical case and literature review , Reumatismo: Early Access
<< < 2 3 4 5 6 7 8 9 10 11 > >>
You may also start an advanced similarity search for this article.